PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Opin Endocrinol Diabetes Obes. Author manuscript; available in PMC Apr 22, 2010.
Published in final edited form as:
PMCID: PMC2858344
NIHMSID: NIHMS193551
Stress and obesity: the role of the hypothalamic–pituitary–adrenal axis in metabolic disease
Mousumi Bose, Blanca Oliván, and Blandine Laferrère
New York Obesity Research Center, St Luke’s Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, New York, USA
Correspondence to Mousumi Bose, PhD, New York Obesity Research Center, St Luke’s Roosevelt Hospital Center, 1111 Amsterdam Avenue, Room 1034, New York, NY 10025, USA, Tel: +1 212 523 3357; fax: +1 212 523 5613; mb3103/at/columbia.edu
Purpose of review
Chronic stress, combined with positive energy balance, may be a contributor to the increased risk for obesity, especially upper body obesity, and other metabolic diseases. This association may be mediated by alterations in the hypothalamic–pituitary–adrenal (HPA) axis. In this review, we summarize the major research that has been conducted on the role of the HPA axis in obesity and metabolic disease.
Recent findings
Dysregulation in the HPA axis has been associated with upper body obesity, but data are inconsistent, possibly due to methodological differences across studies. In addition to systemic effects, changes in local cortisol metabolism in adipose tissue may also influence the risk for obesity. HPA axis dysregulation may be the causal link between conditions such as maternal malnutrition and sleep deprivation with metabolic disease.
Summary
The present review provides evidence for the relationship between chronic stress, alterations in HPA activity, and obesity. Understanding these associations and its interactions with other factors will be important in developing effective treatments for obesity and related metabolic diseases.
Keywords: cortisol, hypothalamic-pituitary-adrenal axis, metabolic syndrome, obesity
The prevalence of obesity has increased dramatically in the USA in the last several decades. Obesity, particularly upper body obesity (UBO), is associated with type 2 diabetes (T2DM), dyslipidemia, and hypertension. These associations describe the metabolic syndrome, a clustering of symptoms with insulin resistance as a core cause [1,2]. Currently, the prevalence of obesity and metabolic syndrome in the USA is 33 [3] and 24% [4], respectively, deeming both conditions important public health issues, requiring immediate efforts to understand these diseases and reduce their occurrence.
Elements of modern society, including western diet, sedentary lifestyle, and environmental stress may contribute to positive energy balance and the development of obesity and metabolic diseases, possibly through dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis.
Stress is a challenge to the natural homeostasis of an organism [5]. Animals react to stress by producing a physiological stress response to regain equilibrium lost by the stressor. The stress response is characterized by acute behavioral and physical adaptations, including increased cognition, analgesia, gluconeogenesis, lipolysis, and inhibition of reproduction [6]. There are two major components of the stress response: the autonomic nervous system (ANS), which encompasses the sympathetic and parasympathetic nervous system, and the HPA axis. These systems work centrally and peripherally to produce several responses. The ‘fight or flight response’ is an active reaction to either confront the stressor or escape confrontation. The ‘defeat response’ is when the individual does not engage in either the fight or flight response and ultimately ‘loses’ the confrontation; this is the primary stress response in modern society and is associated with HPA axis changes [7]. Although the ANS is a key element of the stress response, the purpose of this review is to discuss the role of the HPA axis in obesity and metabolic disease.
Stress can be caused by external stressors such as employment or social strains or by intrinsic stressors such as sleep deprivation. Although an acute short-term stress response is necessary for homeostasis recovery, chronic or prolonged stress responses can be harmful and may cause several disease states [5]. A study on women [8] reported that history of depression was associated with hyperactivity of the HPA axis and decreased bone mineral density. In the past 30 years, numerous studies have shown that obesity and other metabolic risk factors are associated with lower socioeconomic status, job strain, sleep deprivation, and depression [914].
Elegant studies on stress and risk for obesity and metabolic disease in nonhuman primates [15,16] were previously reported. In female cynomologus monkeys fed an atherogenic diet and housed in social groups, subordinate animals (more likely to receive aggression) showed higher visceral adipose tissue (VAT) to subcutaneous adipose tissue (SAT) ratio (suggesting UBO), incidence of atherosclerosis, and ovarian dysfunction compared with non-subordinate animals [17••].
Hypothalamic–pituitary–adrenal axis
The HPA axis is one of two major neuroendocrine systems associated with the stress response. Corticotropin-releasing hormone (CRH), secreted from the para-ventricular nucleus (PVN) of the hypothalamus, stimulates the synthesis of adrenocorticotropin (ACTH) from the anterior pituitary gland. Other hypothalamic ACTH secretagogues are arginine vasopressin and oxytocin, also produced in the PVN [18,19]. Physical stressors such as hypoglycemia, hemorrhage, and immune stimuli activate PVN neurons expressing arginine vasopressin and CRH [20]. ACTH stimulates cortisol production from the adrenal cortex. In addition to these mechanisms of HPA axis activation, studies in the past 15 years have demonstrated that cytokines produced by immune cells or adipocytes can also stimulate the HPA axis, at the level of the hypothalamus, anterior pituitary gland, and the adrenal cortex [6,21]. Cortisol is transported in circulation bound to corticosteroid-binding globulin (CBG) and directed to peripheral target tissues, where its availability is dependent on the activity of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme. The 11β-HSD1 isoform converts the inactive cortisone into active cortisol, and the 11β-HSD2 isoform converts cortisol to the inactive cortisone [22]. Cortisol binds to the glucocorticoid receptor; this complex homodimerizes and translocates to the nucleus, binding to glucocorticoid response elements and modulating transcription of cortisol-responsive genes [6].
The first evidence that cortisol levels may be related to obesity and metabolic disease was based on clinical observations of Cushing’s syndrome; the pathological hypercortisolemia in Cushing’s syndrome is associated with UBO, glucose intolerance [impaired glucose tolerance (IGT)], and hypertension. Adrenalectomy in Cushing’s syndrome patients reverses IGT and obesity [22,23].
Studies in the field of obesity research in the past 10 years have demonstrated that obesity and metabolic syndrome are characterized by chronic inflammation [24]. Pro-inflammatory cytokines can stimulate the HPA axis; conversely, cortisol decreases the production of cytokines and other inflammatory mediators [25,26]. Therefore, it is evident that there exists some crosstalk between the HPA axis and the inflammatory response; this may relate to the role of HPA axis alterations in the development of obesity. A recent study [27•] reported that a higher BMI was associated with decreased anti-inflammatory action of glucocorticoids. Nevertheless, the nature of these relationships remains to be determined.
Clinical assessment of hypothalamic–pituitary–adrenal axis
Of the various methods to assess HPA axis activity, 24-h urinary-free cortisol (UFC) or salivary cortisol, measured at different times of the day (to assess diurnal patterns of cortisol), are preferred to plasma measurements as these are not associated with stress of venipuncture and can be performed in a home setting at various times [28]. In the dexamethasone (a glucocorticoid receptor agonist) suppression test (DST), used to evaluate feedback inhibition of cortisol, 1 mg dexamethasone is given at midnight and plasma cortisol is measured 8 h later [29]. The accuracy of the DST in the determination of HPA axis alterations can be compromised by several conditions. Medications such as phenytoin, phenobarbitone, carbamazepine, and rifampicin increase the hepatic clearance of dexamethasone. Hormone therapy, pregnancy, and oral contraception, by increasing CBG levels, can result in a false-positive DST. Renal and hepatic dysfunction may reduce dexamethasone clearance, and psychiatric conditions such as depression, obesity, alcoholism, and anorexia nervosa may exhibit hypercortisolemia, which may confound dexamethasone suppression [30,31].
Cortisol response in obese patients
HPA axis assessment in common obesity is not performed routinely unless Cushing’s syndrome is suspected. However, there is extensive clinical research on the role of the HPA axis in common obesity. Early studies were inconsistent and showed increased [32] or unchanged [33] 24-h UFC, and no or slight decrease in circulating cortisol levels [23]. More consistent data emerged when comparing patients with UBO with either lean individuals or patients with lower body obesity (LBO). Pasquali et al. [34] demonstrated increased 24-h UFC in women with UBO compared with women with LBO. Similarly, Rosmond et al. [35] reported a significant correlation between postprandial salivary cortisol and BMI, waist-to-hip ratio (WHR), fasting glucose, insulin, triglycerides, cholesterol, and blood pressure in men; similar correlations were demonstrated in morning salivary cortisol levels, BMI, and WHR [36]. Others also reported an increased postprandial salivary cortisol response in women with UBO compared with those with LBO, but no difference in dexamethasone suppression between groups [37]. One study, however, did not find an association of UBO with cortisol levels [38•].
Twenty-four-hour UFC is increased in obese women who gained weight as a result of a stressful event (stress-related obesity, SRO) compared with age-matched and weight-matched obese women without SRO (NSRO) or lean control women [39••], suggesting overactive HPA activity in SRO.
Genetic polymorphisms of hypothalamic–pituitary–adrenal axis in obesity
Currently, there are few genetic polymorphisms that present with both functional alterations in the HPA axis and obesity. Several polymorphisms at the level of ACTH synthesis [40], and in genes associated with glucocorticoid receptor [41,42] or local cortisol metabolism (11β-HSD1 and 11β-HSD2) [22,23,4345], which may predict UBO, have been described. The variability in the heritability of obesity makes it difficult to determine the role of these polymorphisms in common obesity.
Tissue-specific cortisol metabolism: role of 11β-hydroxysteroid dehydrogenase 1 in adipose tissue
The enzyme 11β-HSD1, expressed in several peripheral tissues, including liver and adipose tissue [46], is important in HPA axis activity, regenerating active cortisol from its inactive forms intracellularly. Adipose tissue expression of 11β-HSD1 and regulation of local cortisol levels may play a role in the development of obesity and metabolic disease. Masuzaki et al. [47] found that overexpression of 11β-HSD1 in adipose tissue resulted in visceral obesity and metabolic syndrome in mice when fed a high-fat diet. Furthermore, adipose tissue overexpression of 11β-HSD2, the enzyme that inactivates cortisol, in obesity-prone mice, protected these mice from high-fat diet-induced obesity and IGT [48].
In humans, adipose tissue depot-specific alterations in 11β-HSD1 expression have been reported in obesity, with increased expression of 11β-HSD1 in SAT in obese individuals compared with lean individuals [49,50••]; studies on VAT have been less consistent [5153]. Simonyte et al. [54••] found that SAT 11β-HSD1 expression was significantly higher than in VAT in obese patients. 11β-HSD1 enzyme activity in SAT was positively correlated with waist size, SAT and VAT area, and total adipose tissue area. The depot-specific alterations may be related to the regulation of 11β-HSD1. TNF-α and leptin, adipokines that may be expressed differentially across adipose tissue depots [55,56], have shown to stimulate 11β-HSD1 expression [57,58].
Recently, an elegant study by Stimson et al. [50••] measured cortisol release from different adipose tissue depots and from the liver in men. They found that cortisol release from SAT was substantial, but was undetectable in VAT. The authors concluded that due to feedback control of the HPA axis, this cortisol release from SAT was unlikely to produce systemic effects (which were mainly attributable to liver 11β-HSD1 activity) but rather autocrine and paracrine activities on adipose and surrounding tissues. Nevertheless, its effects on adipose tissue as an endocrine organ remain to be determined.
Interactions with diet and other appetite-regulating hormones
The pathology of obesity is multifactorial, and therefore, it is necessary to understand the various signals and their interactions that contribute to obesity. Leptin, a key adipokine secreted by adipocytes in proportion to fat mass, signals to the central nervous system regarding the status of fat stores to control food intake [59]. Adrenalectomy reduces body weight of obese leptin-deficient ob/ob mice [60], suggesting a role of glucocorticoids in leptin metabolism. Administration of dexamethasone in both lean and obese patients increases serum leptin levels [6163], suggesting that glucocorticoids play a role in the control of hyperleptinemia characteristic of obesity. However, this effect of dexamethasone on leptin levels is seen only under fed conditions [62] or after administration of glucose and insulin [61], demonstrating an interaction of cortisol, insulin, and positive energy balance on leptin regulation.
Leptin levels show a circadian rhythm, with low values during the day and a rise during sleep [64]. It is speculated that the nocturnal rise in leptin serves to suppress appetite. Leptin levels are robustly decreased by sleep deprivation [65]; this reduction may stimulate food intake and ultimately increase the risk for obesity and metabolic disease. Glucocorticoid agonists modulate leptin levels [6163,66], and one study has shown that the decrease in leptin levels after 6 days of sleep restriction (compared with 6-day sleep recovery period) is inversely correlated to 24-h plasma cortisol levels [67].
Ghrelin is a gastric hormone that plays a role in long-term and short-term energy balance and acts centrally to increase food intake. There is a nocturnal increase in ghrelin during sleep deprivation [68] and an inverse relationship between serum ghrelin and serum cortisol levels during 84 h of fasting [69], suggesting that weight gain due to sleep deprivation may be mediated by cortisol and its effects on ghrelin, or vice versa. More studies are necessary to define the relationship between sleep deprivation, cortisol metabolism, appetite-regulating hormones and the development of obesity.
Several studies have examined a potential link between chronic stress and food intake. HPA axis dysregulation has been associated with other eating disorders such as binge eating disorder, bulimia, and anorexia nervosa [7073]. Changes in insulin or neuropeptide Y (NPY) levels, peptides implicated in food intake regulation [74], occur as a result of altered cortisol metabolism [75,76]. Administration of the glucocorticoid prednisone has shown to stimulate food intake in healthy men [77]. Conversely, diet may influence cortisol metabolism. In obese men, cortisol levels increased after weight loss with low calorie high-fat diet, but not after an isocaloric low-fat diet [78]. There are also studies that describe the role of the HPA axis and its effects on food addiction and reward circuitry for palatable foods [22,79,80]. Although not discussed in this review, these are also important areas of research.
Interaction with sex hormones
Body fat distribution is often sex-specific, and UBO is more prevalent in men than women. In women with UBO, the risk for T2DM is significantly greater than in men with UBO [81]. It is possible that sex hormones play a role in HPA axis activity and in the pathology of metabolic disease. A negative association between 24-h mean plasma cortisol levels and body weight in obese women was not seen in obese men. Obese women showed higher CRH-stimulated plasma cortisol levels compared with obese men and cortisol levels were positively correlated with testosterone levels in UBO women, but not UBO men [82]. Estradiol stimulated 11β-HSD1 expression in VAT of women in one study [58] but not in another [83]. Whether the sex-associated differences in cortisol metabolism are related to its depot-specific differences in 11β-HSD1 expression and subsequent local cortisol generation remains to be determined.
Stress experienced in early life may also be a risk factor in the development of obesity and metabolic syndrome. A recent study on nonhuman primates reported that juvenile bonnet macaque monkeys exhibit greater weight, BMI, waist circumference, and insulin resistance if their mothers are exposed to food insecurity when the monkeys are young (age 3–5 months) [84]. An emerging hypothesis in the last several years is that of ‘fetal programming’ that growth and development in utero may predict BMI and adiposity in adulthood. This hypothesis suggests that stress adaptation due to maternal malnutrition during pregnancy, resulting in low birth weight, may increase the risk for obesity and metabolic disease in adulthood [85]. The Dutch famine of 1944 has been extensively studied for evaluation of this hypothesis. Analyses of birth weight and susceptibility for metabolic disease found that in utero exposure to famine resulted in increased incidence of obesity [86,87] and diabetes [88] in adulthood. Recently, another study [89] found an association between postnatal weight gain in preterm babies and glucose-stimulated insulin secretion in adulthood, although there was no relationship between birth weight or gestational age and adult insulin sensitivity.
Animal studies [9092] have shown that dietary restriction in utero results in altered HPA activity and increased glucocorticoid levels as adults. Prenatal exposure to glucocorticoids impairs glucose tolerance in adult rats [9395]. Clinical studies showed increased CRH levels in umbilical cord plasma from growth-retarded children [96]. Birth weight was associated with stress-induced salivary cortisol in 7–9-year-old boys, but not in girls [97]. This association, however, was demonstrated in both middle-aged men and women [98]. Shorter stature, smaller head circumference at birth, and lower BMI at 7 years of age were associated with increased WHR and increased morning salivary cortisol levels in adult men and women [99]. These studies suggest that there may be a relationship with intrauterine growth restriction, HPA activity, and the risk for metabolic disease later in life, although sex and stage of life in which the outcome measure is taken may influence the association.
In the past 30 years, the average nightly sleep duration has decreased from 8–9 to 7 h per night. Currently, 30% of all adults in the USA sleep less than 6 h per night. Sleep deprivation has been linked to both increased risk for obesity and T2DM [65]. Epidemiological studies have reported a negative association between BMI and sleep duration in adults [100102] and children [103,104]. In laboratory studies, insulin sensitivity was reduced in sleep-restricted individuals [105,106]. Sleep deprivation is suggested to be a chronic stressor that may contribute to increased risk for obesity and metabolic diseases, possibly in part through HPA axis dysregulation, although the data are inconsistent. Sleep deprivation resulted in decreased night-time [107] and morning [108] plasma cortisol levels, or increased night-time plasma cortisol levels in other studies [67,109]. To date, there have been no reported studies on the effect of sleep deprivation on salivary cortisol or UFC.
The present review provides basic support for the relationship between chronic stress, alterations in HPA activity, and obesity. Although animal models provide evidence of the association of stress, HPA axis, and metabolic diseases, human studies have proven to be more challenging, with more understated changes in the HPA axis.
In modern society, where overnutrition, sedentary lifestyle, and sleep deprivation are typical traits, chronic exposure to environmental stress potentially contributes to the development of obesity. This may be at least partially mediated through the HPA axis, although this relationship is complex and many factors, including genetic polymorphisms, tissue-specific cortisol metabolism, chronic inflammation, leptin, ghrelin, and sex hormones, influence the strength of this association. Future studies should address the mechanisms that HPA activity dysregulation contributes to obesity and other metabolic complications. Changes in food intake appear to be a primary target. These actions may be related to effects of leptin and other central signals such as NPY and insulin.
HPA axis dysregulation in obesity is subtle and difficult to assess clinically. Continued research in this field is imperative to define a causal role for chronic stress and obesity, and ultimately develop effective treatment or preventive interventions.
Acknowledgments
The present work was funded by National Institute of Health training grant #DK07559.
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 000–000).
1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. [PubMed]
2. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr. 2005;25:391–406. [PubMed]
3. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States – no statistically significant chance since 2003–2004. NCHS Data Brief. 2007:1–8. [PubMed]
4. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006;29:109–117. [PubMed]
5. Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann N Y Acad Sci. 1995;771:665–676. [PubMed]
6. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006;1083:77–110. [PubMed]
7. Bjorntorp P. Visceral obesity: a ‘civilization syndrome’ Obes Res. 1993;1:206–222. [PubMed]
8. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176–1181. [PubMed]
9. Mann JN, Thakore JH. Melancholic depression and abdominal fat distribution: a mini-review. Stress. 1999;3:1–15. [PubMed]
10. Kanjilal S, Gregg EW, Cheng YJ, et al. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971–2002. Arch Intern Med. 2006;166:2348–2355. [PubMed]
11. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29–48. [PubMed]
12. Stranges S, Cappuccio FP, Kandala NB, et al. Cross-sectional versus prospective associations of sleep duration with changes in relative weight and body fat distribution: the Whitehall II study. Am J Epidemiol. 2008;167:321–329. [PMC free article] [PubMed]
13. Brunner EJ, Chandola T, Marmot MG. Prospective effect of job strain on general and central obesity in the Whitehall II study. Am J Epidemiol. 2007;165:828–837. [PubMed]
14. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ. 2006;332:521–525. [PMC free article] [PubMed]
15. Shively CA, Clarkson TB. Regional obesity and coronary artery atherosclerosis in females: a nonhuman primate model. Acta Med Scand Suppl. 1988;723:71–78. [PubMed]
16. Kaufman D, Smith EL, Gohil BC, et al. Early appearance of the metabolic syndrome in socially reared bonnet macaques. J Clin Endocrinol Metab. 2005;90:404–408. [PubMed]
17••. Shively CA, Register TC, Clarkson TB. Social stress, visceral obesity, and coronary artery atherosclerosis in female primates. Obesity (Silver Spring) 2009 in press. This study discusses the higher incidence of atherosclerosis and other metabolic risk factors in female cynomologus monkeys exposed to a model of social stress. [PubMed]
18. Kyrou I, Tsigos C. Stress mechanisms and metabolic complications. Horm Metab Res. 2007;39:430–438. [PubMed]
19. Carter CS. Developmental consequences of oxytocin. Physiol Behav. 2003;79:383–397. [PubMed]
20. Kovacs KJ, Foldes A, Sawchenko PE. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. J Neurosci. 2000;20:3843–3852. [PubMed]
21. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–1362. [PubMed]
22. Nieuwenhuizen AG, Rutters F. The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav. 2008;94:169–177. [PubMed]
23. Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition. 2000;16:924–936. [PubMed]
24. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. [PubMed]
25. Lee SW, Tsou AP, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc Natl Acad Sci U S A. 1988;85:1204–1208. [PubMed]
26. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992;89:9991–9995. [PubMed]
27•. Wirtz PH, Ehlert U, Emini L, Suter T. Higher body mass index (BMI) is associated with reduced glucocorticoid inhibition of inflammatory cytokine production following acute psychosocial stress in men. Psychoneuroendocrinology. 2008;33:1102–1110. This article finds an association with BMI and the reduced anti-inflammatory action of glucocorticoids. [PubMed]
28. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–1540. [PubMed]
29. Nugent CA, Nichols T, Tyler FH. Diagnosis of Cushing’s syndrome; single dose dexamethasone suppression test. Arch Intern Med. 1965;116:172–176. [PubMed]
30. Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA. 1988;259:1699–1702. [PubMed]
31. Vilar L, Freitas Mda C, Faria M, et al. Pitfalls in the diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metabol. 2007;51:1207–1216. [PubMed]
32. Schteingart DE, Conn JW. Characteristics of the increased adrenocortical function observed in many obese patients. Ann N Y Acad Sci. 1965;131:388–403. [PubMed]
33. Strain GW, Zumoff B, Strain JJ, et al. Cortisol production in obesity. Metabolism. 1980;29:980–985. [PubMed]
34. Pasquali R, Cantobelli S, Casimirri F, et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab. 1993;77:341–346. [PubMed]
35. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab. 1998;83:1853–1859. [PubMed]
36. Wallerius S, Rosmond R, Ljung T, et al. Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest. 2003;26:616–619. [PubMed]
37. Duclos M, Marquez Pereira P, Barat P, et al. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res. 2005;13:1157–1166. [PubMed]
38•. Brydon L, Wright CE, O’Donnell K, et al. Stress-induced cytokine responses and central adiposity in young women. Int J Obes (Lond) 2008;32:443–450. This article described an association between stress-induced leptin, IL-1ra, and blood pressure response and upper body obesity, while reporting no association with stress-induced cortisol levels and upper body obesity. [PubMed]
39••. Vicennati V, Pasqui F, Cavazza C, et al. Stress-related development of obesity and cortisol in women. Obesity (Silver Spring) 2009 in press. This study distinguished increased 24 UFC in women with stress-related obesity but not in women with obesity that was not stress-related. [PubMed]
40. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19:155–157. [PubMed]
41. Rosmond R, Chagnon YC, Chagnon M, et al. A polymorphism of the 5’-flanking region of the glucocorticoid receptor gene locus is associated with basal cortisol secretion in men. Metabolism. 2000;49:1197–1199. [PubMed]
42. Weaver JU, Hitman GA, Kopelman PG. An association between a Bc1I restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J Mol Endocrinol. 1992;9:295–300. [PubMed]
43. Gelernter-Yaniv L, Feng N, Sebring NG, et al. Associations between a polymorphism in the 11 beta hydroxysteroid dehydrogenase type I gene and body composition. Int J Obes Relat Metab Disord. 2003;27:983–986. [PubMed]
44. White PC. Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J Clin Endocrinol Metab. 2005;90:5880–5883. [PubMed]
45. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci. 2006;1083:111–128. [PubMed]
46. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25:831–866. [PubMed]
47. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–2170. [PubMed]
48. Kershaw EE, Morton NM, Dhillon H, et al. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes. 2005;54:1023–1031. [PMC free article] [PubMed]
49. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86:1418–1421. [PubMed]
50••. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009;58:46–53. This study reported cortisol release by 11-beta HSD 1 from the subcutaneous adipose tissue and liver, but no detectable release from the visceral adipose depot. [PMC free article] [PubMed]
51. Michailidou Z, Jensen MD, Dumesic DA, et al. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 2007;15:1155–1163. [PubMed]
52. Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007;15:1954–1960. [PubMed]
53. Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab. 2002;87:5630–5635. [PubMed]
54••. Simonyte K, Rask E, Naslund I, et al. Obesity is accompanied by disturbances in peripheral glucocorticoid metabolism and changes in FA recycling. Obesity (Silver Spring) 2009 in press. This study reported increased 11-beta HSD 1 activity in the subcutaneous adipose depot (SAT) in obesity, and a correlation between 11-beta HSD 1 activity in SAT and waist size and adipose tissue area. [PubMed]
55. Arner P. Regional differences in protein production by human adipose tissue. Biochem Soc Trans. 2001;29:72–75. [PubMed]
56. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2005;288:E741–E747. [PubMed]
57. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology. 2001;142:1982–1989. [PubMed]
58. Dieudonne MN, Sammari A, Dos Santos E, et al. Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: sex specificities. J Steroid Biochem Mol Biol. 2006;99:189–196. [PubMed]
59. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology. 2007;132:2103–2115. [PubMed]
60. Dubuc PU, Wilden NJ. Adrenalectomy reduces but does not reverse obesity in ob/ob mice. Int J Obes. 1986;10:91–98. [PubMed]
61. Laferrère B, Caixas A, Fried SK, et al. A pulse of insulin and dexamethasone stimulates serum leptin in fasting human subjects. Eur J Endocrinol. 2002;146:839–845. [PMC free article] [PubMed]
62. Laferrère B, Fried SK, Osborne T, Pi-Sunyer FX. Effect of one morning meal and a bolus of dexamethasone on 24-h variation of serum leptin levels in humans. Obes Res. 2000;8:481–486. [PMC free article] [PubMed]
63. Dagogo-Jack S, Selke G, Melson AK, Newcomer JW. Robust leptin secretory responses to dexamethasone in obese subjects. J Clin Endocrinol Metab. 1997;82:3230–3233. [PubMed]
64. Sinha MK, Ohannesian JP, Heiman ML, et al. Nocturnal rise of leptin in lean, obese, and noninsulin-dependent diabetes mellitus subjects. J Clin Invest. 1996;97:1344–1347. [PMC free article] [PubMed]
65. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287–304. [PubMed]
66. Laferrère B, Abraham C, Awad M, et al. Inhibiting endogenous cortisol blunts the meal-entrained rise in serum leptin. J Clin Endocrinol Metab. 2006;91:2232–2238. [PMC free article] [PubMed]
67. Spiegel K, Leproult R, L’Hermite-Baleriaux M, et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004;89:5762–5771. [PubMed]
68. Dzaja A, Dalal MA, Himmerich H, et al. Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. Am J Physiol Endocrinol Metab. 2004;286:E963–E967. [PubMed]
69. Espelund U, Hansen TK, Hojlund K, et al. Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab. 2005;90:741–746. [PubMed]
70. Birketvedt GS, Drivenes E, Agledahl I, et al. Bulimia nervosa – a primary defect in the hypothalamic-pituitary-adrenal axis? Appetite. 2006;46:164–167. [PubMed]
71. Gluck ME. Stress response and binge eating disorder. Appetite. 2006;46:26–30. [PubMed]
72. Laue L, Gold PW, Richmond A, Chrousos GP. The hypothalamic-pituitary-adrenal axis in anorexia nervosa and bulimia nervosa: pathophysiologic implications. Adv Pediatr. 1991;38:287–316. [PubMed]
73. Lawson EA, Klibanski A. Endocrine abnormalities in anorexia nervosa. Nat Clin Pract Endocrinol Metab. 2008;4:407–414. [PubMed]
74. Porte D, Jr, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002;60:S20–S29. discussion S68–S84, 85–87. [PubMed]
75. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13:803–811. [PubMed]
76. Wake DJ, Homer NZ, Andrew R, Walker BR. Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J Clin Endocrinol Metab. 2006;91:4682–4688. [PubMed]
77. Tataranni PA, Larson DE, Snitker S, et al. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996;271:E317–E325. [PubMed]
78. Stimson RH, Johnstone AM, Homer NZ, et al. Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab. 2007;92:4480–4484. [PubMed]
79. Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91:449–458. [PubMed]
80. Rutters F, Nieuwenhuizen AG, Lemmens SG, et al. Hyperactivity of the HPA axis is related to dietary restraint in normal weight women. Physiol Behav. 2009;96:315–319. [PubMed]
81. Pasquali R, Vicennati V, Gambineri A, Pagotto U. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. Int J Obes (Lond) 2008;32:1764–1779. [PubMed]
82. Vicennati V, Ceroni L, Genghini S, et al. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring) 2006;14:235–243. [PubMed]
83. Friedberg M, Zoumakis E, Hiroi N, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab. 2003;88:385–393. [PubMed]
84. Kaufman D, Banerji MA, Shorman I, et al. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. Diabetes. 2007;56:1382–1386. [PubMed]
85. Barker DJ. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition. 1997;13:807–813. [PubMed]
86. Ravelli AC, van Der Meulen JH, Osmond C, et al. Obesity at the age of 50 y in men and women exposed to famine prenatally. Am J Clin Nutr. 1999;70:811–816. [PubMed]
87. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. N Engl J Med. 1976;295:349–353. [PubMed]
88. Ravelli AC, van der Meulen JH, Michels RP, et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet. 1998;351:173–177. [PubMed]
89. Willemsen RH, Leunissen RW, Stijnen T, Hokken-Koelega AC. Prematurity is not associated with reduced insulin sensitivity in adulthood. J Clin Endocrinol Metab. 2009;94:1695–1700. [PubMed]
90. Lingas RI, Matthews SG. A short period of maternal nutrient restriction in late gestation modifies pituitary-adrenal function in adult guinea pig offspring. Neuroendocrinology. 2001;73:302–311. [PubMed]
91. Lesage J, Blondeau B, Grino M, et al. Maternal undernutrition during late gestation induces fetal overexposure to glucocorticoids and intrauterine growth retardation, and disturbs the hypothalamo-pituitary adrenal axis in the newborn rat. Endocrinology. 2001;142:1692–1702. [PubMed]
92. Bloomfield FH, Oliver MH, Giannoulias CD, et al. Brief undernutrition in late-gestation sheep programs the hypothalamic-pituitary-adrenal axis in adult offspring. Endocrinology. 2003;144:2933–2940. [PubMed]
93. Cleasby ME, Kelly PA, Walker BR, Seckl JR. Programming of rat muscle and fat metabolism by in utero overexposure to glucocorticoids. Endocrinology. 2003;144:999–1007. [PubMed]
94. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978;202:436–438. [PubMed]
95. Nyirenda MJ, Lindsay RS, Kenyon CJ, et al. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest. 1998;101:2174–2181. [PMC free article] [PubMed]
96. Goland RS, Jozak S, Warren WB, et al. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab. 1993;77:1174–1179. [PubMed]
97. Jones A, Godfrey KM, Wood P, et al. Fetal growth and the adrenocortical response to psychological stress. J Clin Endocrinol Metab. 2006;91:1868–1871. [PubMed]
98. Kajantie E, Feldt K, Raikkonen K, et al. Body size at birth predicts hypothalamic-pituitary-adrenal axis response to psychosocial stress at age 60 to 70 years. J Clin Endocrinol Metab. 2007;92:4094–4100. [PubMed]
99. Power C, Li L, Hertzman C. Associations of early growth and adult adiposity with patterns of salivary cortisol in adulthood. J Clin Endocrinol Metab. 2006;91:4264–4270. [PubMed]
100. Bjorvatn B, Sagen IM, Oyane N, et al. The association between sleep duration, body mass index and metabolic measures in the Hordaland Health study. J Sleep Res. 2007;16:66–76. [PubMed]
101. Patel SR, Malhotra A, White DP, et al. Association between reduced sleep and weight gain in women. Am J Epidemiol. 2006;164:947–954. [PMC free article] [PubMed]
102. Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1:e62. [PMC free article] [PubMed]
103. Reilly JJ, Armstrong J, Dorosty AR, et al. Early life risk factors for obesity in childhood: cohort study. BMJ. 2005;330:1357. [PMC free article] [PubMed]
104. Seicean A, Redline S, Seicean S, et al. Association between short sleeping hours and overweight in adolescents: results from a US Suburban High School survey. Sleep Breath. 2007;11:285–293. [PubMed]
105. Spiegel K, Knutson K, Leproult R, et al. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol. 2005;99:2008–2019. [PubMed]
106. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354:1435–1439. [PubMed]
107. Vgontzas AN, Mastorakos G, Bixler EO, et al. Sleep deprivation effects on the activity of the hypothalamic-pituitary-adrenal and growth axes: potential clinical implications. Clin Endocrinol (Oxf) 1999;51:205–215. [PubMed]
108. Wu H, Zhao Z, Stone WS, et al. Effects of sleep restriction periods on serum cortisol levels in healthy men. Brain Res Bull. 2008;77:241–248. [PubMed]
109. Schussler P, Uhr M, Ising M, et al. Nocturnal ghrelin, ACTH, GH and cortisol secretion after sleep deprivation in humans. Psychoneuroendocrinology. 2006;31:915–923. [PubMed]